BeOne Medicines Ltd. ADS (ONC) is trading higher as investors react to a new bullish analyst initiation. Wolfe Research initiated coverage with an Outperform rating and set a $340 price target, framing BeOne as a scaled, profitable oncology company with multiple near-term catalysts that could re-rate the stock.

Wolfe’s thesis centers on breadth and execution speed across BeOne’s oncology pipeline and on the durability of BRUKINSA’s position in chronic lymphocytic leukemia (CLL). The note also points to a 2026 catalyst calendar that includes potential U.S. approval for sonrotoclax in relapsed/refractory mantle cell lymphoma in the first half of 2026, plus additional Phase 3 data events later in the year—creating a steady stream of potential “headline” moments that can drive incremental buyers into the name.

Traders will likely look for follow-through via additional analyst actions, conference presentations, or clinical/regulatory updates tied to the 2026 milestones highlighted in the initiation. With the stock already moving, investors will also monitor whether broader biotech sentiment and risk appetite support continued multiple expansion, or whether the shares revert absent new data-driven developments.